Compare Stocks: INMB, ALEC, MGNX, and GALT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.34 -2.1%	$1.84	$1.09 ▼ $3.40	$261.28M	0.6	1.58 million shs	542,222 shs
GALT Galectin Therapeutics	$4.02 -2.9%	$3.85	$2.03 ▼ $7.13	$264.74M	0.41	349,978 shs	271,118 shs
INMB INmune Bio	$2.33 -2.9%	$1.90	$1.09 ▼ $2.50	$64.67M	0.97	390,631 shs	214,836 shs
MGNX MacroGenics	$4.13 +1.2%	$4.25	$1.29 ▼ $5.08	$263.08M	1.2	508,245 shs	541,658 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-0.85%	+44.44%	+8.33%	-2.50%
GALT Galectin Therapeutics	0.00%	+9.24%	+24.07%	+59.52%	+1.01%
INMB INmune Bio	0.00%	+0.43%	+31.64%	+65.25%	+13.66%
MGNX MacroGenics	0.00%	+0.73%	+9.26%	-0.72%	+140.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.34 -2.1%	$1.84	$1.09 ▼ $3.40	$261.28M	0.6	1.58 million shs	542,222 shs
GALT Galectin Therapeutics	$4.02 -2.9%	$3.85	$2.03 ▼ $7.13	$264.74M	0.41	349,978 shs	271,118 shs
INMB INmune Bio	$2.33 -2.9%	$1.90	$1.09 ▼ $2.50	$64.67M	0.97	390,631 shs	214,836 shs
MGNX MacroGenics	$4.13 +1.2%	$4.25	$1.29 ▼ $5.08	$263.08M	1.2	508,245 shs	541,658 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-0.85%	+44.44%	+8.33%	-2.50%
GALT Galectin Therapeutics	0.00%	+9.24%	+24.07%	+59.52%	+1.01%
INMB INmune Bio	0.00%	+0.43%	+31.64%	+65.25%	+13.66%
MGNX MacroGenics	0.00%	+0.73%	+9.26%	-0.72%	+140.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.13	Hold	$3.63	54.91% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	173.63% Upside
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
MGNX MacroGenics	2.17	Hold	$6.33	53.35% Upside

Current Analyst Ratings Breakdown

Latest INMB, ALEC, MGNX, and GALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	MGNX MacroGenics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $11.00
8/13/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/5/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	MGNX MacroGenics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/31/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/20/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/23/2026	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
6/18/2026	GALT Galectin Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$21.05M	12.41	N/A	N/A	$0.28 per share	8.36
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
INMB INmune Bio	$50K	1,293.15	N/A	N/A	$0.88 per share	2.65
MGNX MacroGenics	$149.50M	1.76	N/A	N/A	$0.88 per share	4.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.10	N/A	N/A	N/A	-850.13%	-531.03%	-44.00%	11/5/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
INMB INmune Bio	-$45.93M	-$0.67	N/A	N/A	N/A	N/A	-82.87%	-62.23%	10/29/2026 (Estimated)
MGNX MacroGenics	-$74.62M	-$0.22	N/A	N/A	N/A	-8.70%	-109.26%	-18.70%	11/11/2026 (Estimated)

Latest INMB, ALEC, MGNX, and GALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/13/2026	Q2 2026	MGNX MacroGenics	-$0.0779	$0.31	+$0.3879	$0.31	$59.14 million	$32.83 million
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	-$0.05	+$0.1567	-$0.05	$1.16 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.26	5.26
GALT Galectin Therapeutics	N/A	0.10	0.10
INMB INmune Bio	N/A	4.04	4.04
MGNX MacroGenics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
GALT Galectin Therapeutics	11.68%
INMB INmune Bio	12.72%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
GALT Galectin Therapeutics	52.60%
INMB INmune Bio	21.40%
MGNX MacroGenics	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	111.66 million	102.39 million	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
INMB INmune Bio	10	27.75 million	21.82 million	Optionable
MGNX MacroGenics	430	63.70 million	55.04 million	Optionable

INMB, ALEC, MGNX, and GALT Headlines

Recent News About These Companies

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts

August 28 at 4:13 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Purchases New Position in MacroGenics, Inc. $MGNX

August 28 at 4:07 AM | marketbeat.com

Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNX

August 26, 2026 | marketbeat.com

MacroGenics (NASDAQ:MGNX) VP Sells $129,085.75 in Stock

August 21, 2026 | insidertrades.com

Insider Selling: MacroGenics (NASDAQ:MGNX) VP Sells 31,105 Shares of Stock

August 20, 2026 | marketbeat.com

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

August 20, 2026 | zacks.com

MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS

August 13, 2026 | marketbeat.com

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

August 13, 2026 | zacks.com

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

August 13, 2026 | globenewswire.com

MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP

August 13, 2026 | marketbeat.com

MacroGenics, Inc.: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 12, 2026 | finanznachrichten.de

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 11, 2026 | globenewswire.com

MacroGenics (MGNX) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Brokerages

August 3, 2026 | marketbeat.com

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

July 27, 2026 | seekingalpha.com

MacroGenics Advances MGC026 in Phase 1 Oncology Trial

July 25, 2026 | theglobeandmail.com

MacroGenics slips after early-stage trial data for lead asset

July 24, 2026 | seekingalpha.com

MacroGenics, Inc.: MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

July 24, 2026 | finanznachrichten.de

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

July 23, 2026 | tmcnet.com

MacroGenics announces upcoming board change with director resignation

July 8, 2026 | tipranks.com

Bora Pharmaceuticals closes 122 million buy of MacroGenics Rockville manufacturing site

July 4, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, ALEC, MGNX, and GALT Company Descriptions

Alector NASDAQ:ALEC

$2.34 -0.05 (-2.09%)

As of 08/28/2026 04:00 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Galectin Therapeutics NASDAQ:GALT

$4.02 -0.12 (-2.90%)

As of 08/28/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

INmune Bio NASDAQ:INMB

$2.33 -0.07 (-2.92%)

As of 08/28/2026 04:00 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

MacroGenics NASDAQ:MGNX

$4.13 +0.05 (+1.23%)

As of 08/28/2026 04:00 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, ALEC, MGNX, and GALT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, ALEC, MGNX, and GALT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, ALEC, MGNX, and GALT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, ALEC, MGNX, and GALT Company Descriptions

Alector NASDAQ:ALEC

Galectin Therapeutics NASDAQ:GALT

INmune Bio NASDAQ:INMB

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, ALEC, MGNX, and GALT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, ALEC, MGNX, and GALT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, ALEC, MGNX, and GALT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, ALEC, MGNX, and GALT Company Descriptions

Alector NASDAQ:ALEC

Galectin Therapeutics NASDAQ:GALT

INmune Bio NASDAQ:INMB

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools